Bibliografie

Detailansicht

Physiologically Based Pharmacokinetic Modeling

Science and Applications
Reddy, Micaela/Yang, R S/Andersen, Melvin E et al
ISBN/EAN: 9780471478140
Umbreit-Nr.: 1975676

Sprache: Englisch
Umfang: 440 S.
Format in cm:
Einband: gebundenes Buch

Erschienen am 15.07.2005
Auflage: 1/2005
€ 189,00
(inklusive MwSt.)
Nachfragen
  • Zusatztext
    • InhaltsangabePreface. Chapter 1.Introduction: A Historical Perspective of the Development and Applications of PBPK Models. 1. Introduction. 2. A Historical Perspective. 3. Expansion of PBPK Model Applications. 4. Summary. SECTION 1. PBPK MODELING FOR VOLATILE ORGANIC COMPOUNDS.# Chapter 2. Halogenated Alkanes. 1. Introduction. 2. PBPK Model Development for Volatile Organics. 3. Advances in Experimental Methods Demonstrated for Groups of Chemicals. 4. PBPK Models for Halogenated Alkanes. 5. Summary. Chapter 3. Halogenated Alkenes. 1. Introduction. 2. The Chloroethylenes: Background. 3. Review of PBPK Models. 4. Summary. Chapter 4. Alkene and Aromatic Compounds. 1. Introduction. 2. PK and Pharmacodynamic Properties Important in PBPK Model Development for Aromatic and Alkene Compounds. 3. Review of Aromatic and Alkene PBPK Models. 4. Summary. Chapter 5. Reactive Vapors in the Nasal Cavity. 1. Introduction. 2. No AirPhase Models. 3. Creating the Air Phase Compartments. 4. Other Models for Vapors Affecting Nasal Tissues. 5. Methyl Methacrylate. 6. Formaldehyde. 7. Hydrogen Sulfide. 10. Summary. Chapter 6. Alkanes, Oxyhydrocarbons and Related Compounds. 1. Introduction. 2. Purposes for PBPK Model Development. 3. PBPK Models for Four Classes of Compounds. 4. Summary. SECTION 2. PBPK MODEL DEVELOPMENT FOR ENVIRONMENTAL POLLUTANTS. Chapter 7. Pesticides and Persistent Organic Pollutants (POPs). 1. Introduction. 2. Pesticides. 3. Polychlorinated and Polybrominated Biphenyls, PCBs and PBBs. 4. Summary. Chapter 8. Dioxin and Related Compounds. 1. Introduction. 2. Toxicity. 3. Mode of Action. 4. Pharmacokinetics. 5. PBPK Models of TCDD. 6. Summary. Chapter 9. Metals and Inorganic Compounds. 1. Introduction. 2. Physiologically Based Modeling of Metals. 3. PBPK Models for Non-Metals. 4. Compartmental Models for Miscellaneous Inorganic and/or Endogenous Chemicals. 5. Research Needs. 6. Summary. SECTION 3. PHARMACEUTICAL APPLICATIONS OF PBPK MODELS. Chapter 10. Drugs. 1. Introduction. 2. Describing the Tissue Distribution of Drugs. 3. Describing Metabolism and Other Clearance Processes of Drugs. 4. Other Issues in Model Development for Drugs. 5. Future Perspectives. 6. Summary. Chapter 11. Antineoplastic Agents. 1. Introduction. 2. PBPK Models for Antineoplastic Agents. 3. Summary. SECTION 4. PBPK MODELING APPROACHES FOR SPECIAL APPLICATIONS. Chapter 12. Perinatal Transfer. 1. Introduction. 2. Physiological and Biochemical Changes During Pregnancy. 3. Physiological Factors Incorporated into PBPK Models for Perinatal Pharmacokinetics. 4. PBPK Models for Perinatal Transfer. 5. Risk Assessment Dosimetry Models. 6. Summary. Chapter 13. Mixtures. 1. Introduction. 2. PBPK Modeling Of Chemical Mixtures. 3. Future Perspectives: Second Generation PBPK/PD modeling. 4. Summary. Chapter 14. Dermal Exposure Models. 1. Introduction. 2. Factors to Consider in Modeling Dermal Absorption. 3. Dermal Absorption Models. 4. Experimental Methods. 5. Summary. Chapter 15. Conclusions and Future Directions. 1. Introduction. 2. A Systems Approach for Pharmacokinetics. 3. Modeling Both Dose and Response. 4. Opportunities for PBPK Modeling in Pharmaceutical Industry. 5. Reaction Network Modeling with Xenobiotics. 6. Systems Biology and Dose-Response. 7. Summary.

  • Kurztext
    • A definitive, single source of information on PBPK modeling Physiologically-based pharmacokinetic (PBPK) modeling is becoming increasingly important in human health risk assessments and in supporting pharmacodynamic modeling for toxic responses. Organized by classes of compounds and modeling purposes so users can quickly access information, this is the first comprehensive reference of its kind. This book presents an overview of the underlying principles of PBPK model development. Then it provides a compendium of PBPK modeling information, including historical development, specific modeling challenges, and current practices for: * Halogenated Alkanes * Halogenated Alkenes * Alkene and Aromatic Compounds * Reactive Vapors in the Nasal Cavity * Alkanes, Oxyhydrocarbons, and Related Compounds * Pesticides and Persistent Organic Pollutants * Dioxin and Related Compounds * Metals and Inorganic Compounds * Drugs * Antineoplastic Agents * Perinatal Transfer * Mixtures * Dermal Exposure Models In addition to pinpointing specific information, readers can explore diverse modeling techniques and applications. An authoritative reference for toxicologists, ecotoxicologists, risk assessors, regulators, pharmacologists, pharmacists, and graduate students in pharmacokinetics and toxicology, Physiologically-Based Pharmacokinetic Modeling compiles information from leaders in the field and discusses future directions for PBPK modeling.

  • Autorenportrait
    • InhaltsangabePreface. Chapter 1.Introduction: A Historical Perspective of the Development and Applications of PBPK Models. 1. Introduction. 2. A Historical Perspective. 3. Expansion of PBPK Model Applications. 4. Summary. SECTION 1. PBPK MODELING FOR VOLATILE ORGANIC COMPOUNDS.# Chapter 2. Halogenated Alkanes. 1. Introduction. 2. PBPK Model Development for Volatile Organics. 3. Advances in Experimental Methods Demonstrated for Groups of Chemicals. 4. PBPK Models for Halogenated Alkanes. 5. Summary. Chapter 3. Halogenated Alkenes. 1. Introduction. 2. The Chloroethylenes: Background. 3. Review of PBPK Models. 4. Summary. Chapter 4. Alkene and Aromatic Compounds. 1. Introduction. 2. PK and Pharmacodynamic Properties Important in PBPK Model Development for Aromatic and Alkene Compounds. 3. Review of Aromatic and Alkene PBPK Models. 4. Summary. Chapter 5. Reactive Vapors in the Nasal Cavity. 1. Introduction. 2. No AirPhase Models. 3. Creating the Air Phase Compartments. 4. Other Models for Vapors Affecting Nasal Tissues. 5. Methyl Methacrylate. 6. Formaldehyde. 7. Hydrogen Sulfide. 10. Summary. Chapter 6. Alkanes, Oxyhydrocarbons and Related Compounds. 1. Introduction. 2. Purposes for PBPK Model Development. 3. PBPK Models for Four Classes of Compounds. 4. Summary. SECTION 2. PBPK MODEL DEVELOPMENT FOR ENVIRONMENTAL POLLUTANTS. Chapter 7. Pesticides and Persistent Organic Pollutants (POPs). 1. Introduction. 2. Pesticides. 3. Polychlorinated and Polybrominated Biphenyls, PCBs and PBBs. 4. Summary. Chapter 8. Dioxin and Related Compounds. 1. Introduction. 2. Toxicity. 3. Mode of Action. 4. Pharmacokinetics. 5. PBPK Models of TCDD. 6. Summary. Chapter 9. Metals and Inorganic Compounds. 1. Introduction. 2. Physiologically Based Modeling of Metals. 3. PBPK Models for Non-Metals. 4. Compartmental Models for Miscellaneous Inorganic and/or Endogenous Chemicals. 5. Research Needs. 6. Summary. SECTION 3. PHARMACEUTICAL APPLICATIONS OF PBPK MODELS. Chapter 10. Drugs. 1. Introduction. 2. Describing the Tissue Distribution of Drugs. 3. Describing Metabolism and Other Clearance Processes of Drugs. 4. Other Issues in Model Development for Drugs. 5. Future Perspectives. 6. Summary. Chapter 11. Antineoplastic Agents. 1. Introduction. 2. PBPK Models for Antineoplastic Agents. 3. Summary. SECTION 4. PBPK MODELING APPROACHES FOR SPECIAL APPLICATIONS. Chapter 12. Perinatal Transfer. 1. Introduction. 2. Physiological and Biochemical Changes During Pregnancy. 3. Physiological Factors Incorporated into PBPK Models for Perinatal Pharmacokinetics. 4. PBPK Models for Perinatal Transfer. 5. Risk Assessment Dosimetry Models. 6. Summary. Chapter 13. Mixtures. 1. Introduction. 2. PBPK Modeling Of Chemical Mixtures. 3. Future Perspectives: Second Generation PBPK/PD modeling. 4. Summary. Chapter 14. Dermal Exposure Models. 1. Introduction. 2. Factors to Consider in Modeling Dermal Absorption. 3. Dermal Absorption Models. 4. Experimental Methods. 5. Summary. Chapter 15. Conclusions and Future Directions. 1. Introduction. 2. A Systems Approach for Pharmacokinetics. 3. Modeling Both Dose and Response. 4. Opportunities for PBPK Modeling in Pharmaceutical Industry. 5. Reaction Network Modeling with Xenobiotics. 6. Systems Biology and Dose-Response. 7. Summary.
Lädt …